1738-68-7

Basic information

• Product Name: GLYCINE BENZYL ESTER HYDROCHLORIDE
• Synonyms: H-Gly-OBzl·HCI;Benzyl Aminoacetate;Glycine Phenylmethyl Ester;Benzyl Glycinate p-Tolylsulfonate;Glycine Phenylmethyl Ester, 4-Methylbenzenesulfonate;H-Gly-OBzl Toluenesulfonate;H-Gly-OBz.HCl;benzyl 2-aminoacetate hydrochloride
• CAS NO: 1738-68-7
• Molecular Formula: C₉H₁₁NO₂
• Molecular Weight: 201.65
• EINECS: 217-092-5
• Product Categories: Amino Acids and Derivatives;Amino Acids 13C, 2H, 15N;Amino Acid Derivatives;Amino Acids & Derivatives;Inhibitors
• Mol File: 1738-68-7.mol

Chemical Properties

• Melting Point: 135-137℃
• Boiling Point: 245.5 °C at 760 mmHg
• Flash Point: 110.3 °C
• Appearance: White solid
• Density: 1.132 g/cm³
• Vapor Pressure: 0.0146mmHg at 25°C
• Refractive Index: 1.558
• Storage Temp.: −20°C
• PKA: 7.30±0.29(Predicted)
• CAS DataBase Reference: GLYCINE BENZYL ESTER HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: GLYCINE BENZYL ESTER HYDROCHLORIDE(1738-68-7)
• EPA Substance Registry System: GLYCINE BENZYL ESTER HYDROCHLORIDE(1738-68-7)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 1738-68-7(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Potent crosslinking inhibitors

InChI:InChI=1/C9H11NO2/c1-12-9(11)7-10-8-5-3-2-4-6-8/h2-6,10H,7H2,1H3

Upstream product

• 1138-80-3 N-(Benzyloxycarbonyl)glycine 
• 56-40-6 glycine 
• 100-51-6 benzyl alcohol 
• 100-39-0 benzyl bromide 
• 173601-46-2 benzyl 2-azidoacetate 
• 946132-45-2 C₂₁H₁₈N₂O₄ 
• 2462-31-9 benzyl 2-aminoacetate hydrochloride 
• 63366-76-7 (toluene-4-sulfonylamino)acetic acid benzyl ester 
• 100-46-9 benzylamine 
• 4530-20-5 BOC-glycine 
• 381238-74-0 9-xanthenylmethoxycarbonyl glycine benzyl ester 
• 54244-69-8 tert-butoxycarbonylamino-acetic acid benzyl ester 
• 1738-76-7 glycine benzyl ester p-toluenesulfonic acid salt 
• 5513-38-2 benzyl N-benzyloxycarbonylglycinate 

Downstream Products

• 115209-46-6 N-[N⁵-benzyloxycarbonyl-N²-(toluene-4-sulfonyl)-L-ornithyl]-glycine benzyl ester 
• 103097-59-2 N-[(S)-4-benzyloxycarbonylamino-2-(toluene-4-sulfonylamino)-butyryl]-glycine benzyl ester 
• 115291-84-4 N-(N²-benzoyl-N⁶-benzyloxycarbonyl-L-lysyl)-glycine benzyl ester 
• 92507-13-6 N.N'-bis-benzyloxycarbonyl-L-cystine bis-(benzyloxycarbonylmethyl-amide) 
• 23513-91-9 Z-D,L-Ser-Gly-O-benzylester 
• 57294-43-6 Cbz-Phe-Gly-OBn 
• 188624-38-6 benzyl ureidoacetate 
• 103163-42-4 N-(toluene-4-sulfonyl)=>glycyl=>(2-amino-4-phthalimido-butyryl)=>glycine-benzyl ester 
• 101280-97-1 (2RS,3SR)-2-amino-3-hydroxy-3-(4-nitro-phenyl)-propionic acid benzyl ester 
• 62147-24-4 N-(trans-1-benzyloxycarbonyl-4-hydroxy-L-prolyl)-glycine-benzyl ester 
• 19811-58-6 benzoylamino-acetic acid benzyl ester 
• 120548-57-4 N-(1-benzyl-N^α-benzyloxycarbonyl-L-histidyl)-glycine-benzyl ester 
• 94359-70-3 benzyl N-phenylacetylglycinate 
• 2601-46-9 Z-L-Cys(Bzl)-Gly-OBzl 

Relevant articles and documents

Lipase sensing by naphthalene diimide based fluorescent organic nanoparticles: a solvent induced manifestation of self-assembly

The precise control of supramolecular self-assembly is gaining utmost interest for the demanding applications of manifested nano-architecture across the scientific domain. This study delineates the morphological transformation of naphthalene diimide (NDI) derived amphiphiles with varying water content in dimethyl sulfoxide (DMSO) and the selective sensing of lipase using its aggregation-induced emission (AIE) properties. To this end, NDI-based, benzyl alcohol protected alkyl chain (C1, C5, and C10) linked amphiphilic molecules (NDI-1,2,3) were synthesized. Among the synthesized amphiphiles, benzyl ester linked C5 tailored naphthalene diimide (NDI-2) exhibited AIE with an emission maximum at 490 nm in a DMSO-water binary solvent system fromfw= 30% and above water content. The fibrous morphology ofNDI-2atfw= 30% got gradually transformed to spherical aggregated particles along with steady increment in the emission intensity upon increasing the amount of water in DMSO. Atfw= 99% water in DMSO, complete transformation to fluorescent organic nanoparticles (FONPs) was observed. Microscopic and spectroscopic techniques demonstrated the solvent driven morphological transformation and the AIE property ofNDI-2. Moreover, this AIE ofNDI-2FONPs was employed in the selective turn-off sensing of lipase against many other enzymes including esterase, through hydrolysis of a benzyl ester linkage with a limit of detection 10.0 ± 0.8 μg L?1. TheNDI-2FONP also exhibited its lipase sensing efficiencyin vitrousing a human serum sample.

DRUGS TO TREAT OCULAR DISORDERS

The present invention provides new prodrugs of therapeutically active loop diuretics, including oligomeric prodrugs, and compositions to treat medical disorders, for example, ocular disorders such as glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

MACROCYCLIZATION OF PEPTIDOMIMETICS

The invention provides an improved method of macrocyclization of peptidomimetics, as measured by isolated yields and product distribution, which comprises substitution of one or more of the backbone amide C=O bonds with a turn-inducing motif. The method is general with enhancements seen across a range of ring sizes (e.g. tri-, tetra-, penta- and hexapeptides). Specifically, the invention provides a peptidomimetic macrocycle comprising a carbonyl bioisosteric turn-inducing element having the structure: (I) wherein X is a heteroatom; and wherein R1 to R6 are each independently selected from alkyl, aryl, heteroaryl and H.

11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.

METHOD FOR INHIBITING GROWTH OF CANCER CELLS

1 A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Aktl, ERK2 and serine2152-phosphorylated filamin A are contacted

Synthesis of poly(ester-amide) dendrimers based on 2,2-Bis(hydroxymethyl) propanoic acid and glycine

Water-soluble, biodegradable, and biocompatible poly(ester-amide) dendrimers with hydroxyl functional groups are synthesized from previously prepared AB2 adduct of 2,2-bis(hydroxymethyl) propanoic acid (bis-MPA) and glycine as a repeating unit. Two esterification procedures using different coupling reagent/catalyst systems (DCC/DPTS or EDC/DMAP) are studied with respect to efficiency, ease of products purification, and quality of the final products. Both procedures have their own benefits and drawbacks, depending on dendrimer generation. The synthesized poly(ester-amide) dendrimers as well as commercially available bis-MPA dendrimers, poly(ester-amide) hyperbranched polymer, and poly(vinyl alcohol) are used for preparation of solid dispersions of sulfonylurea antidiabetic drug glimepiride to improve its poor water-solubility. In vitro dissolution studies show in comparison with pure glimepiride in crystalline or amorphous form, to the same extent improved glimepiride solubility for solid dispersions based on dendritic polymers, but not for poly(vinyl alcohol). The amount of glimepiride complexed with both dendrimer types increases with dendrimer generation.

SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES

There are provided compounds of the formula wherein X, Y, Z, R1, R2, R3 and R4 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

A self-assembled complex with a Titanium(IV) catecholate core as a potential bimodal contrast agent

A ditopic chelating ligand (H64) that bears catechol and diethylenetriamine-N,N,N',N',N'-pentaacetate (DTPA) has been designed and shown to specifically bind lanthanide(III) ions at the DTPA core ([Ln(H 24)(H2O)]-/su

RADIOLABELLING METHOD USING CYCLOALKYL GROUPS

This invention relates to novel cyclo alkyl compounds suitable for labeling by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

A class of novel conjugates of substituted purine and Gly-AA-OBzl: Synthesis and evaluation of orally analgesic activity

Aimed at the chemotherapy of chronic pain two kinds of analgesic pharmacophores, substituted purine and Gly-AA-OBzl, were coupled via a five-step-reaction procedure and 19 novel conjugates N-[2-chloro-9- (tetrahydropyran-2-yl)-9H-purin-6-yl]-N-cyclopropylglycylamino acid benzylesters were provided. On mouse-tail flick model their in vivo analgesic activities were assayed. The results indicate that introducing Gly-OC2H 5 into the 6-position of the substituted purine leads to ambiguous increase of the analgesic activity, while introducing Gly-AA-OBzl into this position leads to significant increase of the analgesic activity.